Information  X 
Enter a valid email address

Evgen Pharma PLC (EVG)

  Print   

Wednesday 08 December, 2021

Evgen Pharma PLC

Grant of Options

RNS Number : 0150V
Evgen Pharma PLC
08 December 2021
 

Evgen Pharma plc

("Evgen" or the "Company")

 

Grant of Options

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 8 December 2021, certain employees and directors of the Company, including the following Persons Discharging Managerial Responsibility ("PDMR"), were granted nil cost options (the "Options") over a total of 4,302,975 ordinary shares in the Company exercisable, subject to the Options vesting, for a period of up to 10 years from the date of grant and governed by the rules of the Evgen Pharma plc Long Term Incentive Plan ("LTIP").

 

PDMR

Position

Options granted

Dr Huw Jones

Chief Executive Officer

1,670,886

Richard Moulson

Chief Financial Officer

552,911

Dr Glen Clack

Chief Medical Officer

632,911

Dr Helen Kuhlman

Chief Business Officer

708,861

Nick Mallard

Vice President, Project Leadership

612,089

 

The Options will vest on the third anniversary of grant based on performance against challenging strategic corporate objectives over three years (40%), share price growth (30%) and on an elapsed time basis at 3 years (30%).

 

Following this award there are 9,786,980 options in issue, representing 3.56% of the Company's issued share capital.

 

Enquiries:

Evgen Pharma  plc  www.evgen.com  

via Walbrook  

Barry Clare, Chairman 


Richard Moulson, CFO 




finnCap  www.finncap.com  

+44 (0)20 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance) 


Alice Lane (ECM) 




Walbrook PR  

+44 (0)20 7933 87870 or  [email protected]

Paul McManus / Anna Dunphy 

+ 44 (0)7980 541 893 / +44 (0)7876 741 001 

 

Notes for editors:

 

About Evgen Pharma plc

 

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

 

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/  

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dr Huw Jones

2

Reason for the notification

a)

Position/status

Chief Executive

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma Plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

1,670,886


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

8 December 2021

g)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Moulson

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

552,911


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

8 December 2021

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Glen Clack

2

Reason for the notification

a)

Position/status

Chief Business Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

632,911


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

8 December 2021

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Helen Kuhlman

2

Reason for the notification

a)

Position/status

Chief Business Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

708,861


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

8 December 2021

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Nick Mallard

2

Reason for the notification

a)

Position/status

VP Project Management

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over ordinary shares of 0.25 pence each

 

 GB00BSWYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

612,089


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

 

 

f)

Date of the transaction

8 December 2021

g)

Place of the transaction

London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKFBKQBDDABK

a d v e r t i s e m e n t